Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Ocuphire Pharma Inc (OCUP)

Ocuphire Pharma Inc (OCUP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 75,255
  • Shares Outstanding, K 17,300
  • Annual Sales, $ 0 K
  • Annual Income, $ -24,620 K
  • 60-Month Beta 0.15
  • Price/Sales 127.73
  • Price/Cash Flow N/A
  • Price/Book 3.40
Trade OCUP with:

Options Overview Details

View History
  • Implied Volatility 143.97%
  • Historical Volatility 88.13%
  • IV Percentile 97%
  • IV Rank 84.06%
  • IV High 158.30% on 08/20/21
  • IV Low 68.39% on 09/23/21
  • Put/Call Vol Ratio 0.07
  • Today's Volume 4,833
  • Volume Avg (30-Day) 1,815
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 10,676
  • Open Int (30-Day) 1,083

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate -0.29
  • Number of Estimates 1
  • High Estimate -0.29
  • Low Estimate -0.29
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.35 +29.85%
on 11/23/21
5.50 -20.91%
on 11/24/21
+0.28 (+6.88%)
since 10/26/21
3-Month
3.35 +29.85%
on 11/23/21
5.50 -20.91%
on 11/24/21
-0.07 (-1.58%)
since 08/26/21
52-Week
3.35 +29.85%
on 11/23/21
13.81 -68.51%
on 02/03/21
-1.87 (-30.06%)
since 11/25/20

Most Recent Stories

More News
Ocuphire Announces Enrollment of First Patients in Second Phase 3 Pivotal Trial (MIRA-3) for Nyxol® in Reversal of Mydriasis (RM)

RM Indication Allows for Rapid Recruitment with Top-line Results Expected in Early 2022 Nyxol has the Potential Opportunity to Address Estimated $500M+...

OCUP : 4.35 (+5.20%)
Ocuphire Pharma, Inc. (OCUP) Loses 17.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Ocuphire Pharma, Inc. (OCUP) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts...

OCUP : 4.35 (+5.20%)
Ocuphire Invited to Present Clinical Data on Nyxol® and APX3330 at the American Academy of Ophthalmology 2021 Annual Meeting and Eyecelerator/AAO Meeting

FDA Approves First Pharmaceutical Therapy to Treat Presbyopia; Nyxol on Track to Start Phase 3 Presbyopia Trials in First Half of 2022 Ocuphire Uniquely...

OCUP : 4.35 (+5.20%)
Ocuphire Pharma Presenting at Three Upcoming Healthcare Conferences This Fall

Benzinga Healthcare Small Cap Conference on September 29-30, 2021

OCUP : 4.35 (+5.20%)
Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

FARMINGTON HILLS, Mich., Sept. 03, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), today announced that the Compensation Committee of its Board of Directors, which is composed entirely...

OCUP : 4.35 (+5.20%)
Ocuphire Pharma Presenting at Four Conferences in September

Euro Forums 2021 Virtual Retina Forum on September 8, 2021

OCUP : 4.35 (+5.20%)
Ocuphire Announces Financial Results for the Second Quarter 2021 and Provides Corporate Update

Continued Momentum in Nyxol ® Programs with Announcement of Positive Top-Line Results from VEGA-1 Phase 2 Trial in Presbyopia

PCSA : 5.53 (-3.15%)
OCUP : 4.35 (+5.20%)
Ocuphire Pharma Presenting at Two Conferences in August

Canaccord Genuity 41 st Annual Growth Conference being held virtually on August 10-12, 2021

OCUP : 4.35 (+5.20%)
Ocuphire Announces Publication in the Journal of Cellular Signaling Featuring its Oral Ref-1 Inhibitor APX3330 in Phase 2 Trial for the Treatment of Retinal Disease

Highlights Favorable Safety Profile of the Oral New Chemical Entity APX3330 and Its Novel Anti-Angiogenic and Anti-Inflammatory Mechanism of Action Properties Relevant to a Broad Range of Retinal Diseases...

OCUP : 4.35 (+5.20%)
Ocuphire Selected to Present at Multiple Ophthalmic Conferences in July

Positive Results from Phase 2 Presbyopia (VEGA-1) and Phase 3 Reversal of Mydriasis (MIRA-2) Studies to be Presented at 2021 ASCRS Annual Meeting in Las Vegas

OCUP : 4.35 (+5.20%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Ocuphire Pharma Inc. is a clinical-stage ophthalmic biopharmaceutical company. It is focused on developing and commercializing therapies for the treatment of several eye disorders. The company's product pipeline includes Nyxol Eye Drops(R) and APX3330. Ocuphire Pharma Inc., formerly known as Rexahn Pharmaceuticals...

See More

Key Turning Points

3rd Resistance Point 5.36
2nd Resistance Point 5.00
1st Resistance Point 4.68
Last Price 4.35
1st Support Level 4.00
2nd Support Level 3.64
3rd Support Level 3.32

See More

52-Week High 13.81
Fibonacci 61.8% 9.82
Fibonacci 50% 8.58
Fibonacci 38.2% 7.35
Last Price 4.35
52-Week Low 3.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar